Jungsu Kim

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5713141/publications.pdf

Version: 2024-02-01

63	8,204	87723 38	133063 59
papers	citations	h-index	g-index

73	73	73	11446
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The Role of Apolipoprotein E in Alzheimer's Disease. Neuron, 2009, 63, 287-303.	3.8	1,251
2	Human apoE Isoforms Differentially Regulate Brain Amyloid-Î² Peptide Clearance. Science Translational Medicine, 2011, 3, 89ra57.	5.8	924
3	CHIP and Hsp70 regulate tau ubiquitination, degradation and aggregation. Human Molecular Genetics, 2004, 13, 703-714.	1.4	613
4	AÎ²42 Is Essential for Parenchymal and Vascular Amyloid Deposition in Mice. Neuron, 2005, 47, 191-199.	3.8	524
5	AÂ40 Inhibits Amyloid Deposition In Vivo. Journal of Neuroscience, 2007, 27, 627-633.	1.7	327
6	Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. Journal of Clinical Investigation, 2008, 118, 671-82.	3.9	301
7	Serotonin signaling is associated with lower amyloid-Î² levels and plaques in transgenic mice and humans. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 14968-14973.	3.3	281
8	Attenuating astrocyte activation accelerates plaque pathogenesis in APP/PS1 mice. FASEB Journal, 2013, 27, 187-198.	0.2	254
9	APOE4-specific Changes in AÎ² Accumulation in a New Transgenic Mouse Model of Alzheimer Disease. Journal of Biological Chemistry, 2012, 287, 41774-41786.	1.6	213
10	Overexpression of Low-Density Lipoprotein Receptor in the Brain Markedly Inhibits Amyloid Deposition and Increases Extracellular AÎ² Clearance. Neuron, 2009, 64, 632-644.	3.8	212
11	Bifunctional Compounds for Controlling Metal-Mediated Aggregation of the AÎ²₄₂ Peptide. Journal of the American Chemical Society, 2012, 134, 6625-6636.	6.6	187
12	Control of Cholesterol Metabolism and Plasma High-Density Lipoprotein Levels by microRNA-144. Circulation Research, 2013, 112, 1592-1601.	2.0	187
13	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	5.8	170
14	Haploinsufficiency of Human APOE Reduces Amyloid Deposition in a Mouse Model of Amyloid-Î² Amyloidosis. Journal of Neuroscience, 2011, 31, 18007-18012.	1.7	166
15	miR-106b impairs cholesterol efflux and increases AÎ² levels by repressing ABCA1 expression. Experimental Neurology, 2012, 235, 476-483.	2.0	161
16	Low-density Lipoprotein Receptor Represents an Apolipoprotein E-independent Pathway of AÎ² Uptake and Degradation by Astrocytes. Journal of Biological Chemistry, 2012, 287, 13959-13971.	1.6	152
17	Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease. Current Opinion in Lipidology, 2017, 28, 60-67.	1.2	123
18	Anti-apoE immunotherapy inhibits amyloid accumulation in a transgenic mouse model of AÎ² amyloidosis. Journal of Experimental Medicine, 2012, 209, 2149-2156.	4.2	120

#	Article	IF	Citations
19	Mercaptoacetamide-based class II HDAC inhibitor lowers AÎ² levels and improves learning and memory in a mouse model of Alzheimer's disease. Experimental Neurology, 2013, 239, 192-201.	2.0	117
20	The effect of Cu2+ and Zn2+ on the AÎ²42 peptide aggregation and cellular toxicity. Metallomics, 2013, 5, 1529.	1.0	114
21	Apolipoprotein E in Synaptic Plasticity and Alzheimerâ€™s Disease: Potential Cellular and Molecular Mechanisms. Molecules and Cells, 2014, 37, 767-776.	1.0	113
22	Insights into the mechanisms of action of antiâ€AÎ² antibodies in Alzheimer's disease mouse models. FASEB Journal, 2006, 20, 2576-2578.	0.2	110
23	BRI2 (ITM2b) Inhibits AÂ Deposition In Vivo. Journal of Neuroscience, 2008, 28, 6030-6036.	1.7	110
24	miR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1). Molecular Neurodegeneration, 2016, 11, 55.	4.4	106
25	microRNA-33 Regulates ApoE Lipidation and Amyloid-Î² Metabolism in the Brain. Journal of Neuroscience, 2015, 35, 14717-14726.	1.7	104
26	Anti-ApoE Antibody Given after Plaque Onset Decreases AÎ² Accumulation and Improves Brain Function in a Mouse Model of AÎ² Amyloidosis. Journal of Neuroscience, 2014, 34, 7281-7292.	1.7	102
27	Shared genetic risk between corticobasal degeneration, progressive supranuclear palsy, and frontotemporal dementia. Acta Neuropathologica, 2017, 133, 825-837.	3.9	90
28	miRâ€186 is decreased in aged brain and suppresses <scp>BACE</scp>1 expression. Journal of Neurochemistry, 2016, 137, 436-445.	2.1	78
29	Normal cognition in transgenic BRI2-AÎ² mice. Molecular Neurodegeneration, 2013, 8, 15.	4.4	74
30	Mitochondrial ATP synthase activity is impaired by suppressedO-GlcNAcylation in Alzheimer's disease. Human Molecular Genetics, 2015, 24, 6492-6504.	1.4	74
31	Blocking the Interaction between Apolipoprotein E and AÎ² Reduces Intraneuronal Accumulation of AÎ² and Inhibits Synaptic Degeneration. American Journal of Pathology, 2013, 182, 1750-1768.	1.9	70
32	Amyloid precursor protein-induced axonopathies are independent of amyloid-Î² peptides. Human Molecular Genetics, 2008, 17, 3474-3486.	1.4	68
33	MicroRNA 7 Impairs Insulin Signaling and Regulates AÎ² Levels through Posttranscriptional Regulation of the Insulin Receptor Substrate 2, Insulin Receptor, Insulin-Degrading Enzyme, and Liver X Receptor Pathway. Molecular and Cellular Biology, 2019, 39, .	1.1	51
34	Apolipoprotein E as a Î²-amyloid-independent factor in Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2013, 5, 38.	3.0	48
35	Acoustofluidic assembly of 3D neurospheroids to model Alzheimer's disease. Analyst, The, 2020, 145, 6243-6253.	1.7	44
36	Small Bifunctional Chelators That Do Not Disaggregate Amyloid Î² Fibrils Exhibit Reduced Cellular Toxicity. Inorganic Chemistry, 2014, 53, 11367-11376.	1.9	43

#	Article	IF	Citations
37	In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS. PLoS ONE, 2012, 7, e38013.	1.1	43
38	Blocking the apoE/AÎ² interaction ameliorates AÎ²-related pathology in APOE Îµ2 and Îµ4 targeted replacement Alzheimer model mice. Acta Neuropathologica Communications, 2014, 2, 75.	2.4	42
39	Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy. Acta Neuropathologica Communications, 2020, 8, 72.	2.4	42
40	Tubular human brain organoids to model microglia-mediated neuroinflammation. Lab on A Chip, 2021, 21, 2751-2762.	3.1	41
41	Analysis of Extracellular RNA by Digital PCR. Frontiers in Oncology, 2014, 4, 129.	1.3	38
42	Blocking the apoE/AÃŸ interaction ameliorates AÃŸ-related pathology in APOE Â¿2 and Â¿4 targeted replacement Alzheimer model mice. Acta Neuropathologica Communications, 2014, 2, 75.	2.4	36
43	Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival. Scientific Reports, 2016, 6, 23326.	1.6	31
44	The E3 ubiquitin ligase Idol controls brain LDL receptor expression, ApoE clearance, and AÎ² amyloidosis. Science Translational Medicine, 2015, 7, 314ra184.	5.8	30
45	Prion-Like Behavior of Amyloid-Î². Science, 2010, 330, 918-919.	6.0	26
46	Deletion of Abi3 gene locus exacerbates neuropathological features of Alzheimerâ€™s disease in a mouse model of AÎ² amyloidosis. Science Advances, 2021, 7, eabe3954.	4.7	26
47	Common Pesticide, Dichlorodiphenyltrichloroethane (DDT), Increases Amyloid-Î² Levels by Impairing the Function of ABCA1 and IDE: Implication for Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 46, 109-122.	1.2	25
48	APOE Genotype Differentially Modulates Effects of Anti-AÎ², Passive Immunization in APP Transgenic Mice. Molecular Neurodegeneration, 2017, 12, 12.	4.4	25
49	Measurement of apolipoprotein E and amyloid Î² clearance rates in the mouse brain using bolus stable isotope labeling. Molecular Neurodegeneration, 2012, 7, 14.	4.4	23
50	A Mercaptoacetamide-Based Class II Histone Deacetylase Inhibitor Increases Dendritic Spine Density via RasGRF1/ERK Pathway. Journal of Alzheimer's Disease, 2016, 51, 591-604.	1.2	21
51	MicroRNAs in brain cholesterol metabolism and their implications for Alzheimer's disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 2139-2147.	1.2	18
52	Intra- and Inter-individual Variability of microRNA Levels in Human Cerebrospinal Fluid: Critical Implications for Biomarker Discovery. Scientific Reports, 2017, 7, 12720.	1.6	18
53	Ultrastructural studies in APP/PS1 mice expressing human ApoE isoforms: implications for Alzheimer's disease. International Journal of Clinical and Experimental Pathology, 2012, 5, 482-95.	0.5	13
54	Special issue on neurodegenerative diseases and their therapeutic approaches. Experimental and Molecular Medicine, 2015, 47, e146-e146.	3.2	5

#	Article	IF	Citations
55	Differential Effects of ApoE Isoforms on Dendritic SpinesIn Vivo: Linking an Alzheimer's Disease Risk Factor with Synaptic Alterations. Journal of Neuroscience, 2010, 30, 4526-4527.	1.7	4
56	The roles of GxxxG motif and gamma-secretase components in APP processing. Interdisciplinary Bio Central, 2009, 1, 1-7.	0.1	2
57	MicroRNAs on the move: microRNAs in astrocyte-derived ApoE particles regulate neuronal function. Neuron, 2021, 109, 907-909.	3.8	2
58	Role of Autophagy in Alzheimerâ€™s Disease. Current Enzyme Inhibition, 2013, 9, 55-66.	0.3	1
59	O5-03-01: Apolipoprotein E Genotype Differentially Modulates Effects of ANTI-AB Immunotherapy. , 2016, 12, P381-P382.		1
60	Tutorial on Drug Development for Central Nervous System. Interdisciplinary Bio Central, 2010, 2, 9.1-9.5.	0.1	0
61	P4â€059: Agingâ€Associated Micrornaâ€186â€5P Regulates Abeta Level Through Bace1. Alzheimer's and Dementia, 2016, 12, P1037.	0.4	0
62	[P4â€“125]: THE MOLECULAR CHAPERONE BRICHOS INHIBITS AÎ² AGGREGATION AND OTHER NEUROPATHOLOGICAL PHENOTYPES IN A MOUSE MODEL OF AÎ² AMYLOIDOSIS. Alzheimer's and Dementia, 2017, 13, P1304.	0.4	0
63	Editorial (Hot Topic Therapeutic Targets in Neurodegenerative Diseases). Current Enzyme Inhibition, 2013, 9, 1-2.	0.3	0